What is Glaukos?
Glaukos is a ophthalmic medical technology company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Ophthalmic medical technology company
- Headquarters
- Aliso Viejo, United States
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; NYSE: GKOS
What is Glaukos?
Glaukos is a ophthalmic medical technology company company headquartered in Aliso Viejo, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Glaukos is a ophthalmic medical technology company company headquartered in Aliso Viejo, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Glaukos should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Glaukos offer?
Glaukos's profile centers on Glaucoma devices, Corneal health, Ophthalmic implants, Surgical technology.
- Glaucoma devices· Ophthalmic medical technology company
- Corneal health· Ophthalmic medical technology company
- Ophthalmic implants· Ophthalmic medical technology company
- Surgical technology· Ophthalmic medical technology company
- Eye care· Ophthalmic medical technology company
- Clinical development· Ophthalmic medical technology company
How does Glaukos make money?
Glaukos makes money through commercial activity tied to ophthalmic medical technology company.
Glaukos monetizes through the model common to ophthalmic medical technology company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Glaukos?
Glaukos's named executives should be verified on the official leadership or investor-relations page before outreach.
- Glaukos executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Glaukos finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Glaukos operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Glaukos's leadership?
Glaukos should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.glaukos.comHow is Glaukos funded?
Glaukos's current status is Public company; NYSE: GKOS.
Glaukos's capital profile is best understood through its current public-company status: Public company; NYSE: GKOS. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Glaukos get here?
Glaukos's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingGlaukos is foundedThe company begins building in ophthalmic medical technology company.
- Scale-upCommercial footprint expandsGlaukos broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; NYSE: GKOSPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Glaukos's competitors?
Glaukos competes with larger incumbents and focused specialists in ophthalmic medical technology company.
Glaukos — frequently asked questions
